Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study.

Analysis of a new anti-depression mechanism of Chaigui granules based on multi-omics integration: In-depth mining of intestinal microbiota-metabolite interaction network.

Advances in the discovery of selective NaV1.8 inhibitors for pain management.

A comprehensive strategy of network pharmacology and molecular docking reveals Danshenol a as a main active component of Huoluoxiaolingdan in ameliorating acute myocardial infarction.

Engineered potent DC vaccine enables closer DC-T cell contact to trigger personalized antitumor immunity.

Mitochondria-targeted carbon monoxide delivery nanoplatform for enhanced cancer immunotherapy through metabolic-immune reprogramming.

Huashi Baidu granules alleviates LPS-induced acute lung injury by targeting TACE-mediated inflammatory signaling and stress granules disassembly.

ReCell, is a skin processing device that produces an autologous skin cell suspension (ASCS), which has shown promise in enhancing skin regeneration for patients with burn injuries. Despite its growing use in clinical practice, the current literature displays considerable variability in study design and quality, leading to ongoing uncertainty about its true clinical effectiveness. This systematic review and meta-analysis aims to comprehensively evaluate the clinical efficacy of ReCell's ASCS technology in the treatment of burns. A systematic review was conducted in accordance with PRISMA guidelines, using searches across PubMed, Web of Science, Embase, and Cochrane databases. The review protocol was prospectively registered on PROSPERO (CRD42024606554). The Cochrane Risk of Bias Tool and the ROBINS-I tool were applied to assess bias in randomized controlled trials and observational studies, respectively. The overall methodological quality of included studies was appraised using the GRADE framework. Fourteen studies (n = 3362) fulfilled the inclusion criteria. The pooled mean patient age was 38.35years, with a male predominance (69.8%). The average %TBSA affected was 14.6% (95% CI: 8.76-20.44), with substantial heterogeneity (I2 = 95.1%). Meta-analysis demonstrated a statistically significant reduction in complication rates with ASCS combined with split-thickness skin grafting (STSG) compared to STSG alone (RR = 0.64, 95% CI: 0.41-1.00, P = .048). However, rates of wound infection and graft failure did not differ significantly between groups. ASCS demonstrates potential to reduce complications in burn care. Nevertheless, due to heterogeneous study designs, further high-quality, large-scale randomized trials are warranted to validate its long-term efficacy and broader clinical utility.

Objective.During radiotherapy, the radiation dose delivered to circulating blood can result in radiation-induced lymphopenia, which is correlated with adverse clinical outcomes like lower survival. Increasingly complex models to simulate radiation dose delivery to circulating blood have been developed in response, and their inclusion during radiotherapy treatment planning has been suggested. However, performing full dynamic blood dose simulations which take into account temporal considerations such as blood flow dynamics and treatment delivery time during the iterative treatment planning process is currently infeasible. This work presents a quasi-instantaneous deep learning-based approach to estimate blood dose simulation results to allow for their inclusion during treatment planning.Approach.We used treatment planning computed tomography images and dose-volume histograms of 157 head-and-neck cancer patients to perform dynamic blood dose simulations (HEDOS). Subsequently, a deep neural network composed of fully-connected layers and a Transformer encoder was trained to estimate the blood dose distribution obtained from HEDOS, using the same inputs as HEDOS. We used 126 patients' data for training and internal validation and the remaining 31 patients' data for testing. To evaluate the proposed method, we calculated the Kullback-Leibler (KL) divergence between the prediction results and the ground truth data. Additionally, we compared the minimum dose delivered to 90% of the blood particles receiving the highest dose (D90%) to estimate the model's clinical efficacy.Main results.The average and standard deviation of KL divergence between the prediction and the ground truth were 0.099 and 0.092, respectively. The D90%calculated from the predicted distribution showed a mean-absolute-percentage error of 4.60% compared to the ground truth.Significance.A deep learning-based model capable of accurately and quasi-instantaneously predicting the results of dynamic blood dose simulations was developed, paving the way for the inclusion of dynamic blood dose simulations during radiotherapy treatment planning.

The mechanistic role of Poria cocos in cancer treatment: Antitumor activity and adjuvant potential in chemotherapy.

Sarcopenia, the age-related loss of skeletal muscle mass and function, poses a major health challenge. While leucine's anabolic properties are well documented, its clinical efficacy as a standalone intervention remains limited. This review explores the potential of integrated strategies combining leucine with other nutrients, physical activity, and gut microbiota modulation to enhance sarcopenia prevention and treatment. Recent studies confirm that leucine supplementation alone fails to significantly improve muscle mass or strength in older adults. However, its benefits emerge when combined with resistance training, or gut microbiota-targeted interventions. The gut-muscle axis has gained attention as a key modulator of muscle health. Additionally, leucine supports the resumption of physical activity in sarcopenic patients by mitigating exercise-induced muscle damage and inflammation. These findings underscore the need for multimodal approaches, leucine, optimized nutrition, exercise, and microbiota modulation, to maximize therapeutic benefits. Future research should focus on defining optimal dosages, personalized protocols, and clinical feasibility. Such strategies could revolutionize sarcopenia management by integrating innovative, patient-centred care.

A randomised study examining the utility of lauromacrogol foam sclerotherapy vs pingyangmycin in treatment of pediatric lymphatic malformations --a single center report from China.

Therapeutic potential of traditional Chinese medicine for the treatment of chemotherapy-induced diarrhea: clinical efficacy and underlying mechanisms

Isobavachalcone ameliorates TNBS-induced Crohn's disease-like colitis via GPR84-PI3K-AKT axis.

The innovative application of 3D-printed spinal braces in post-percutaneous vertebroplasty care for osteoporotic vertebral compression fractures: A retrospective study.

Therapeutic potential of traditional herbal medicine against multidrug-resistant pulmonary infections: Based on clinical and pharmacodynamic evidence.

Modern trends of using innovative nanoparticle approaches for immune-based osteosarcoma therapy.

Artificial intelligence in oncological positron emission tomography: advancing image analysis and interpretation.

Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials. A conceptual framework for personalized lipid management is proposed, addressing residual cardiovascular risk, statin intolerance, and complex patient profiles. Clinical decision pathways are presented for high-risk patients, statin-intolerant individuals, and those with adherence challenges. We explore emerging therapies targeting novel pathways, including lipoprotein(a), apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, and gene-editing technologies. Implementation barriers, including cost considerations, insurance challenges, and global access disparities, are discussed alongside solutions.

The genus Caralluma: Traditional use, phytochemistry, nutritional value, pharmacology, nanoformulation, and toxicology.